Total 2 articles
Novartis enters a $1.7 billion Novartis SciNeuro Alzheimer deal 2026 to develop next-gen anti-amyloid treatments using blood-brain barrier shuttle technology.
A Canadian pharmacy platform is now offering India-sourced Ozempic to US patients, aiming to bypass high domestic costs and supply shortages. Explore the impact on the pharma market.
Advertise with Us
